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ABSTRACT
This study was undertaken to investigate the uptake and metabolism
of free cobalamin (vitamin B^) by cultured human skin fibroblasts.

It

was shown that normal diploid fibroblasts in culture take up free
cobalamin (Cbl) via a saturable, mediated process which is inhibited by
sulfhydryl reagents and inhibitors of protein synthesis but which is
relatively unaffected by inhibitors of glycolysis and respiration.
Cobalamin taken up in this manner becomes associated with intracel1ular
Cbl-dependent apoenzymes.

A similar process was shown to occur in

skin fibroblasts from patients with a deficiency of transcobalamin II
(TC II), the plasma protein which mediates the normal process of
Cbl uptake.

It was observed that normal skin fibroblasts in culture

synthesize TC II and secrete it into incubation medium.

Synthesis

of the transport protein does not occur in fibroblasts from TC IIdeficient patients, indicating that the observed uptake process for
free Cbl is not mediated by TC II.

A mechanism by which an uptake

process for free Cbl might serve a function in normal Cbl metabolism
is proposed.
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INTRODUCTION
The elucidation of pathways of intermediary metabolism has often
been closely linked to the study of clinical phenomena arising from
circumscribed lesions, congenital or acquired, which disrupt the normal
sequence of metabolic events.

Perhaps no system better portrays this

interplay of clinical observation and biochemical investigation than the
study of the metabolism of cobalamin (vitamin B.^).

The observation in

1926 that liver extracts could be used to treat megaloblastic anemia (1)
led to the further understanding of the role of vitamin

and gastric

intrinsic factor deficiency in the pathophysiology of pernicious anemia
and culminated in the isolation of the vitamin in 1948 (2).

Since that

time, inborn errors have been observed involving almost every aspect of
cobalamin metabolism and their study has fostered the evolving understand¬
ing of the normal metabolic processes involved in the molecule's ab¬
sorption, transport, and conversion to active coenzymes.
This study was designed to explore further one aspect of cobalamin
metabolism and it too has its roots in the investigation of the patho¬
physiology of an inborn metabolic defect.

It has been observed that

patients with a congenital deficiency of the transport protein (transcobalamin II) responsible for the cellular uptake of cobalamin, who have
the symptoms of severe cobalamin deficiency, respond to pharmacologic
doses of vitamin B-^, thus suggesting that cells are capable of taking up
and utilizing free as well as protein-bound cobalamin.

These observations

prompted this in vitro investigation of the uptake and metabolism of free
cobalamin by human fibroblasts with the goal of further illuminating
the normal processes of cobalamin metabolism while explaining the ob¬
served pathologic phenomena in the clinical model.

1

An understanding of current concepts of cobalamin metabolism
depends on a grasp of the salient features of the vitamin's structure
and function.

The remainder of this introduction will survey relevant

aspects of the chemistry of the cobalamin compounds, their metabolism,
and their function as intracellular cofactors, and includes a brief dis¬
cussion of the clinical features of cobalamin-related metabolic disease.

Chemical Structure of Cobalamin
The complex three-dimensional structure of cobalamin (vitamin Bp)
was elucidated using x-ray crystallography in 1956 by Hodgkin et al.

(3).

The molecule (Fig. 1) consists of a planar corrin ring around a central
cobalt atom, with a side chain extending below the plane of the ring.
The side chain contains a 5,6-dimethylbenzimidazole ring with ribose
and phosphate moieties, and attaches via a Co-N coordination linkage
to the benzimidazole ring.
to the corrin ring.

The phosphate moiety provides a second link

The different cobalamin compounds are character¬

ized by the radicals in covalent linkage to the cobalt nucleus above
the plane of the corrin ring.
mammals:

Three such compounds have been found in

hydroxocobalamin, methylcobalamin, and adenosylcobalamin.

The

commonly isolated form, cyanocobalamin, is not found in vivo and is an
artifact of isolation.
The central cobalt atom of the cobalamin molecule can exist in a
monovalent, divalent, or trivalent state.

Hydroxocobalamin, the naturally

occurring form of the vitamin, has a trivalent cobalt atom; in its
metabolism to the active coenzyme compounds, adenosylcobalamin and
methylcobalamin, the cobalt must be reduced to a monovalent state.
sequential reduction from Co

to Co

-
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in the formation of

This

FIGURE 1.

Structure of the cobalamin molecule.

R = CH^CONH^; R'

CH^CH^CONH^; X = -OH,-CU,-CH3> or 51-deoxy-5'-adenosyl.

-
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adenosylcobalamin has been shown in bacteria to be mediated by specific
enzymes (4); this process, and the evidence for similar cobalamin re¬
ductases in mammalian cells, will be discussed in connection with the
metabolism of adenosylcobalamin.

Adenosylcobalamin and Methylmalonate Metabolism
Adenosylcobalamin (AdoCbl) was the first cobalamin coenzyme to be
described and partially purified.

In 1958, Barker et al. (5) described

a coenzyme form of "pseudovitamin B^" required for the isomerization
of glutamate to 3-methyl aspartate in Clostridium tetanomorphum.
Isolation yielded a substance which, on exposure to light, released
adenine and a substance with an absorption spectrum similar to cobalamin.
The coenzyme, adenosylcobalamin, has 51-deoxy-5'-adenosyl in the sixth
coordination position of the cobalamin molecule.

Adenosylcobalamin and

methylcobalamin are unique in that they are the only naturally occurring
substances known to have a direct carbon-cobalt bond.
A role, for AdoCbl as a coenzyme in mammals--specifically, for the
conversion of methylmalonyl CoA to succinyl CoA--was proposed in 1958 by
Smith and Monty (6) and subsequently confirmed (7,8).

Gurnani et al.

(7)

reported that mitochondrial preparations of livers from cobalamindeficient rats showed normal rates of methylmalonate formation but
markedly reduced rates of succinate production; addition of "vitamin B-^
cofactor" (AdoCbl) restored this activity in vitro.

Stern and Friedman

(8) reported similar results in ox liver fractions.
Methylmalonyl CoA mutase, the enzyme for which AdoCbl is a coenzyme,
converts methylmalonyl CoA to succinyl CoA.

Methylmalonyl CoA is an

intermediate in the pathway of propionate metabolism, as well as a

- 4 -

product of thymine metabolism.

Thymine is only a minor source of

methylmalonyl CoA; the main contribution to the intracellular production
of methylmalonyl CoA is from propionyl CoA, an intermediate in the final
common pathway for the catabolism of branched chain amino acids, choles¬
terol, and odd chain fatty acids (9) (see Fig. 2).
The metabolism of OH-Cbl to AdoCbl was first studied in bacteria.
Walter et al. described specific reductases responsible for the sequential
reduction of cob[111]a1amin to cob[I]alamin in cell-free extracts of
C. tetanomorphum (4); they reported two NADH-dependent flavoproteins
distinguishable on the basis of their cofactor requirements and
thermolability.

Subsequently, they reported isolation and purification

of a Cbl-specific adenosyltransferase (10).

Hence, evidence favors a

three-step metabolic pathway for the production of AdoCbl in bacteria:
two sequential reductions of OH-Cbl followed by adenosylation of
cob[I[alamin; each step requires a specific enzyme.
In higher animals, AdoCbl synthesis has been shown to be a mito¬
chondrial process:

Mahoney et al. (11) reported AdoCbl synthetic

capability in mitochondria-enriched subcellular fractions of fibro¬
blasts in a system which bypassed the first reduction step; subsequently,
Fenton and Rosenberg (12) have shown that intact, purified rat liver
mitochondria can convert OH-Cbl to AdoCbl without bypassing any part
of the pathway.

Despite these studies, efforts to confirm an enzymatic

pathway similar to that in bacteria have been unsuccessful to date.
However, indirect evidence that the pathway for the synthesis of AdoCbl
is enzymatic is provided by the observation of inborn errors of metabolism
which result in an inability to convert OH-Cbl to AdoCbl

- 5 -
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Methylcobalamin and Homocysteine Metabolism
In 1956, Helleiner and Woods (14) reported the facilitation of
methionine synthesis by adding Cbl to cell-free extracts of E. coli.
Ten years later, Weissbach and Taylor (15) reported that methylcobalamin
(MeCbl) is a cofactor in the remethylation of homocysteine to methionine;
they isolated a cobamide-enzyme complex with transmethylase activity
5
from E. coli which, in the presence of N -methyltetrahydrofolate and Sadenosylmethionine, could generate methionine from homocysteine (16)
x

(see Fig. 3).
a

14

14

Using

C-labelled methyltetrahydrofolate, they demonstrated

C-methylcobalamin-enzyme intermediate and proposed a mechanism by

which the methyl group is transferred first from methyltetrahydro¬
folate to the Cbl-enzyme complex, and subsequently to homocysteine.
The transfer of the methyl group to the Cbl-enzyme complex is facilitated
by the reduction of the Co

"I"

to Co , which generates a strong

nucleophile (15,16).
The significance of this cobalamin dependent reaction is twofold:
in addition to the metabolism of homocysteine to methionine, the methyltransferase reaction serves as a source for the regeneration of demethylated
tetrahydrofolate.

Through a mechanism which is still not clearly

established, this link to the pathway of folate metabolism plays an
important role in the clinical manifestations of disorders of cobalamin
metabolism (9).

This will be discussed further with those disorders.

Cobalamin Metabolism
The synthesis of cobalamin (Cbl) is restricted to microorganisms;
consequently, higher animals must derive Cbl from dietary sources or from
their intestinal flora.

The mammalian mechanism of transport, uptake,

"
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and metabolism of Cbl is an elaborate one which carefully conserves and
maximally utilizes the trace quantities of the vitamin present in the
external environment.

The absorption of dietary Cbl is facilitated by

gastric intrinsic factor (IF), a glycoprotein secreted by the gastric
mucosa which competes for the Cbl in ingested animal protein and binds
the vitamin in the intestinal lumen (17).

The successful trapping of Cbl

by IF appears to depend on partial acid digestion of the ingested protein,
because some achlohydric and post-partial gastrectomy patients malabsorp
protein-bound Cbl despite normal absorption of crystalline Cbl (18).
The IF-Cbl complex then binds to ileal receptors via a rapid, Ca++dependent process which is unaffected by temperature or metabolic inhibi¬
tors (19,20).

The receptors are specific for the IF-Cbl complex;

binding is unaffected by the presence of large excesses of free Cbl,
free IF, or other Cbl-binders found in plasma, saliva, granulocytes,
and breast milk (21).

However, the affinity of the complex for the

receptor is apparently unchanged by binding of other Cbl compounds to
IF; if a Cbl compound can effectively bind to IF, the complex can bind
to the intestinal wall (22).
Once bound to the ileal receptors, Cbl is absorbed by a poorlyunderstood mechanism by which the vitamin is taken into and transported
across the intestinal epithelial cell.

It is not clear whether or not

IF is taken up with the Cbl, and little is known about the intracel1ular
transport of the vitamin, but it is ultimately released free into the
portal blood (23,24).

This phase of absorption is slow; although the

IF-Cbl complex associates with ileal receptors within minutes, peak
plasma levels of Cbl are not achieved until about eight hours after
ingestion (25).

-
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The free Cbl is immediately bound by plasma globulins as it enters
the bloodstream.

Almost all newly absorbed Cbl binds to transcobalamin

(TC II), a 3-globulin isolated in 1963 by Hall and Finkler (26).

TC II

is synthesized by the liver and possibly by other organs (27,28) and
represents 80-100% of unsaturated Cbl-binding capacity in human plasma
(23).

Cobalamin bound to TC II has a rapid turnover rate and most

disappears from plasma within a few hours (29).
absorbed Cbl binds to transcobalamin I (TC I), an
to be derived from granulocytes (30).

The remainder of newlya-globulin thought

TC I is one of the "R binder"

proteins--a series of Cbl binders with identical amino acid sequences,
which can be distinguished by their associated carbohydrate moieties,
and which are secreted by a number of tissues including granulocytes,
saliva, and breast milk (31,32).

The functional significances of

these secretory binding proteins is unclear (23).

The TC I-bound Cbl

turns over very slowly and when newly absorbed vitamin comes into
equilibrium with total body Cbl, TC I-bound Cbl represents 75 percent
of Cbl in plasma (33).
When Hall and Finkler first reported the isolation of TC II in
1963, they suggested that it might prove important in the movement of
Cbl from the gut to other tissues (26).

Since that time, the TC II-

Cbl complex has been studied extensively both in vivo and in vitro.
TC II has been shown to facilitate the uptake of Cbl by HeLa cells
(34), erythrocytes (35), Ehrlich ascites tumor cells (36), L1210
leukemia cells (37), and cultured human fibroblasts (38).
Like the absorption of the IF-Cbl complex, TC 11-Cbl uptake has been
shown to be a biphasic process.

Parenchych and Cooper (36,39) showed

that TC 11-Cbl uptake by Ehrlich ascites cells and by HeLa cells

- 9 -

II

consists of a rapid, Ca

++

-dependent, temperature- and

energy-independent

phase followed by a slower, temperature-dependent process which can be
inhibited metabolically.

They suggested that the first component

represents binding to a membrane receptor--a passive, physico-chemical
reaction, and that the second component corresponds to internalization-an active transport process.

Youngdahl-Turner and colleagues (40)

studied the kinetics of these two components separately in cultured human
fibroblasts, and provided strong evidence of this interpretation.
Studies at 4° showed saturable, Ca++-dependent binding specific for the
TC II moiety of the complex.

More than 95 percent of the Cbl bound could

be released by trypsin, indicating that Cbl is not internalized at 4°;
internalization occurred at 37° by a process which was pH-dependent
and inhibited by metabolic inhibitors of endocytosis (40,41).

Studies

with double-labelled ^I-TC II-CN-[5^Co]Cbl showed that both labels
were taken up simultaneously, suggesting that the TC 11-Cbl complex is
taken up intact (41).
Pletsch and Coffey (42) studied the mechanism of uptake of the
TC 11-Cbl complex by cell fractionation studies of rat liver after
intravenous injection of Cbl, and reported a transient association
of Cbl with lysosomal fractions preceding its appearance in large
quantities in the mitochondrial and soluble fractions.

Further

evidence for the association with lysosomes is provided by the obser¬
vation that chloroquine, an inhibitor of lysosomal activity, prevents
the release of Cbl from TC 11-Cbl complex and consequently inhibits
the synthesis of coenzymes (41).
Thus, evidence has accumulated to suggest the following sequence of
events:

1) the TC II-Cbl complex binds to specific receptors on the

10
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cell surface; 2) the complex is taken up intact via adsorptive endocytosis; 3) the endocytotic vesicle fuses with a lysosome; and 4) the
TC II-Cbl complex is degraded, allowing release of free Cbl into the cyto¬
sol with subsequent conversion to active coenzymes (41,42).

The mechanism

by which free Cbl is transported out of the lysosome and into mito¬
chondria is unknown.

r

Clinical Features of Cobalamin Related Disorders
The clinical manifestations of Cbl-related disorders are pleomorphic.
The clinical features of vitamin deficiency usually differ widely from
the findings associated with inborn errors affecting intracel1ular co¬
enzyme activity; it is this dissociation which suggests that Cbl may
well serve another as yet undetermined function in mammals.

I will

first discuss the cardinal manifestations of Cbl deficiency--megaloblastic
anemia and neurologic degeneration, and the primary presenting signs
of disorders of intracellular Cbl metabolism--methylmalonic acidemia
(-uria), homocystinemia (-uria), and ketoacidosis; I will then describe
the manifestations of TC II deficiency and its implications with regard
to the metabolic consequences of this inborn error.
Megaloblastic Anemia -- Megaloblastic changes involve all formed
elements of blood and are usually associated with either Cbl or folate
deficiency, though they may occur as a result of other metabolic disorders
which impair DNA synthesis (43).

Megaloblastic anemia is characterized by

a normochromic, macrocytic anemia, leukopenia with hypersegmented poly¬
morphonuclear leukocytes, and thrombocytopenia.

The pancytopenia is

primarily a result of ineffective hematopoiesis (43-45); in the erythroid series,
peripheral hemolysis also plays a role.

-11

The bone marrow is normocel1ular

or hypercellular and shows megaloblastic transformation of all cell
lines.

The hallmark of the megaloblastic process is "nuclear-cytoplasmic

asynchronism" (43)—the development of cells with mature cytoplasmic
elements and an immature nucleus.

Erythrocytes are large with mature

cytoplasm--appearing either basophilic or containing hemoglobin,
with fine granular nuclei characteristic of early phases of erythroid
maturation.

Leukocytes and megakaryocytes are less dramatically changed

in appearance, but also show signs of nuclear-cytoplasmic asynchronism,
as well as increased marrow destruction (44,45).
The pathophysiologic basis for megaloblastosis is thought to be
impaired DNA synthesis with resultant unbalanced growth, maturation arrest,
and cell death.

The primary lesion is probably a defect in the synthesis

of DNA precursors, notably thymidine (46), resulting in impairment of
DNA synthesis in the absence of a block in RNA synthesis.

Megaloblastic

cells have greatly increased amounts of RNA with normal levels of DNA
(47); DNA synthesis can be increased in vitro by the addition of
precursors (48,49).

Studies of bacterial systems with isolated impaired

ability to make deoxyribonucleosides have shown the consequences to be
unbalanced growth, increased cell size, increased RNA content and very
slow DNA synthesis.

This leads to slow and abnormal proliteration,

and rapidly decreasing viability (50).

The same process appears to

occur in Cbl- or folate-deficient bone marrow.

Maturation of erythrocytes

in megaloblastic anemia is delayed, there is disruption of the normal
cell cycle, with a prolongation of the G1 (pre-DNA synthesis) phase and
delay of the S (DNA-synthetic) phase (48,49,51).

The cells enlarge, and

are predisposed to abnormal maturation and/or early death.
can be reversed by thymidine (52), folate, or Cbl.

-
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This process

The etiology of impaired DMA synthesis in megaloblastic anemia is
not well established.
Cbl and folate.

The most intriguing clue lies in the link between

Megaloblastic anemia occurs with deficiency of either

folate or Cbl, and pharmacologic doses of one can partially or completely
reverse the megaloblastosis induced by deficiency of the other.

This

interrelationship implies strongly that the basis of megaloblastic trans¬
formation lies in a Cbl-dependent part of the folate pathway.
5
As mentioned earlier, N -methyltetrahydrofolate is converted to
tetrahydrofolate during the methylation of homocysteine to form methionine
This reaction is the basis for the "methylfolate trap" hypothesis of the
etiology of megaloblastosis proposed by Noronha and Silverman in 1961 (53)
They propose that Cbl deficiency limits the Droduction of demethylated
tetrahydrofolate, "trapping" available folate compounds in methyltetrahydrofolate.

This limits the availability of other folate compounds

for intracellular metabolism--notably in megaloblastic anemia, it cur¬
tails the supply of tetrahydrofolate needed for the conversion of dUMP
to dTMP by thymidylate synthetase.
one:

The

hypothesis is an attractive

it fits with the theory of pathogenesis of megaloblastosis and

explains the response to thymidine, folate, and Cbl in deficiencies of
either of the latter two compounds without invoking as-yet-undiscovered
Cbl-dependent pathways.
Much confliciting data has been generated in efforts to confirm this
hypothesis (43).

In vitro studies of the conversion of dUMP to dTMP in

bone marrow cells have shown the reaction to be Cbl-dependent (54);
methyl transferase activity is reportedly decreased in the liver of
Cbl-deficient rats (55); serum levels of N -methyltetrahydrofolate was
elevated and clearance delayed in a group of patients with Cbl

-
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deficiency (56); and isolated congenital deficiency of methyl transferase
has been associated with megaloblastic anemia (57).

All this evidence

tends to support the proposed "folate trap" mechanism.

On the other

hand, other measurements of methyltetrahydrofolate utilization in Cbldeficient patients by studies of clearance and

12

CO^ generation from

^CH^-tetrahydrofolate have shown normal turnover of the methylated com¬
pound and have failed to confirm that plasma levels are elevated (58,59).
Most difficult to explain are the data provided by children with an in¬
born error of Cbl metabolism resulting in failure to synthesize either
AdoCbl or MeCbl:

of the four reported cases of this disorder, only one

child had evidence of megaloblastic anemia (60-63).

Thus, though the

role of Cbl deficiency in megaloblastic anemia is probably mediated
by a link to the pathway of folate metabolism, the relationship is not
straightforward, and the possibility that Cbl has a completely separate
role in some other aspect of folate metabolism has not been ruled out.
Neurologic Disorders -- The hallmark of the neurological disorder
associated with Cbl deficiency is "subacute combined degeneration" of
the spinal cord--a diffuse, uneven degeneration of myelin sheaths and
axon cylinders beginning usually in the posterior columns of the thoracic
cord and spreading to the lateral tracts and up and down the cord.

The

clinical syndrome has its onset in symmetric weakness and paresthesias
of the distal extremities and progresses to ataxic and spastic paraplegia,
the predominance of ataxia or spasticity depending on the relative
involvement of the posterior and lateral tracts.

The peripheral signs

may be associated with a full range of cerebral manifestations, includ¬
ing irritability, apathy, intellectual deterioration, and psychosis (64).

14
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Little is known of the pathophysiology of subacute combined degen¬
eration.

The lack of correlation between neurologic symptoms and mega-

loblastosis, and the observation that folate can reverse the latter but
not the former, have led investigators to believe the Cbl-deficiencyinduced demyelination is mediated either through the AdoCbl/methylmalonyl
CcA pathway, or through some different mechanism not directly related to
either known Cbl-dependent pathway.

There are two major pathogenic

mechanisms which have been proposed.

One suggests that Cbl deficiency

blocks the metabolism of methylmalonyl CoA and that accumulation of
this compound either inhibits myelin synthesis, or leads to the incor¬
poration of the molecule into abnormal lipids with subsequent synthesis
of defective myelin.

The other possibility put forward is that Cbl plays

a crucial role in the detoxification of cyanide and that subacute com¬
bined degeneration is a manifestation of chronic cyanide intoxication
secondary to deficiency of the detoxifying mechanism (43).
The first hypothesis has been supported by several in vitro
studies of fatty acid synthesis; abnormal fatty acids have been shown
to be made, in the setting of Cbl deficiency, by rat liver extracts
(65), rat glial cells in culture (66), and nerve biopsy slices (67).
Once again, however, the clinical manifestations of inborn errors of
Cbl metabolism cast doubt on the validity of the theory.

Patients

with defects in the apoenzyme of methylmalonyl CoA mutase or with
defects in the synthesis of AdoCbl present with severe methylmalonic
acidemia, but are free of the stigmata of subacute combined degenera¬
tion (9).
The cyanide intoxication theory has its roots in the observation
that OH-Cbl can combine with cyanide in plasma and can even serve as

15
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an antidote in cyanide poisoning (68,69).

The arguments in favor of the

failure of this clearance mechanism as the basis of neuropathology in Cbl
deficiency rest mainly on the observations of neurologic disorders in
cigarette smokers and notably, on observations of the syndrome of tobacco
amblyopia, an

insidious progression of visual impairment associated

with optic atrophy (70,71).

Cigarette smokers have an increased CM

load, high levels of thiocyanate excretion, and a susceptibility to
tobacco amblyopia with mild Cbl deficiency.

These observations have

been supplemented by other reports of neurologic disorders associated
with populations exposed to high levels of dietary cyanide (43).
Clinical syndromes of inborn errors of Cbl metabolism serve once again
to show that the situation is not so simple.

Although the cyanide theory

explains why children with isolated errors of AdoCbl metabolism show
no signs of subacute combined degeneration, it fails to explain why two
of the four children with combined AdoCbl and MeCbl deficiency, but
normal serum Cbl levels, did have neurologic symptoms.

This argues for

the involvement of one of the intracel1ular pathways of Cbl metabolism
in the pathogenesis of this disorder.
Metabolic Ketoacidosis -- Methylmalonic acid excretion is elevated
in a large proportion of patients with Cbl deficiency (72), and has
been considered a sensitive test which often distinguishes Cbl and
folate deficiency (73).

The methylmalonic acid excretion in these patients,

however, is rarely severe and is not associated with obvious clinical
manifestations.

By contrast, children with inborn errors of metabolism

leading to deficient activity of methylmalonyl Co- mutase, either due to
defects in apoenzyme function or coenzyme synthesis, excrete massive
quantities

of methylmalonic acid and characteristically present with

-
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episodes of 1ife-threatening ketoacidosis, often associated with
hypoglycemia, hyperammonemia, and hyperglycinemia (9,74,75).
The pathogenesis of ketoacidosis in these children is not fully
understood.

The accumulation of methylmalonic acid is easily explained

by the block in the conversion of methylmalonyl CoA to succinyl CoA; it
also explains why one might expect some elevation of this intermediate
to be present in Cbl deficiency.

Why this should lead to the other

aspects of the syndrome is less obvious, and proposed mechanisms rely
on the further role of the mutase reaction in carbohydrate metabolism.
Accumulation of methylmalonyl CoA may reduce the availability of coenzyme
A and consequently the supply of acetyl CoA for the TCA cycle.

Methyl¬

malonic acid is an inhibitor of gluconeogenesis, both by direct inhi¬
bition of pyruvate carboxylase and by inhibition of the mitochondrial
transport of malate, the precursor of oxaloacetate (76).

In addition

to causing hypoglycemia, this contributes to the disruption of carbo¬
hydrate metabolism; the combined block of the TCA cycle and gluconeogenesis could lead to increased lipolysis and ketoacidosis.

The

mechanisms of hyperglycinemia and hyperammonemia are unknown (9).

Clinical Manifestations of Transcobalamin II Deficiency
In 1971, Hakami et al. (77) described two siblings who presented
at three and five weeks of age with diarrhea, vomiting, and "failure
to thrive".

Both were found to have severe megaloblastic anemia in the

face of normal serum folate and Cbl levels; both responded dramatically
to high doses of intramuscular Cbl with complete clinical and hemato¬
logic recovery.
TC II.

The infants were found to have a complete absence of

A similar case has been described since (78).
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In both cases,

pedigree analysis of the families and laboratory studies of their
serum suggest a single gene defect with an autosomal recessive mode of
inheritance.
In the older of the two index cases, withdrawal of therapy was
attempted at one year of age.
and the study was stopped.

Megaloblastic anemia recurred in six weeks,

During this interval, biochemical determina¬

tions in urine and plasma revealed no increase in methylmalonic acid ex¬
cretion , no rise in the blood levels of homocysteine, methionine, or
cystathione, and no change in the rate of succinate or propionate oxida¬
tion by peripheral leukocytes (79).

Despite florid megaloblastic

changes, the metabolic variables that reflect the Cbl-dependent pathways
remained entirely normal.
Given the crucial role of TC II in the cellular uptake of Cbl, one
might expect the presentation of TC II deficiency to resemble most
closely that of children with a combined intracellular defect of coenzyme
synthesis, who present with methylmalonic acidemia and homocystinuria.
In reality, the complete absence of detectable biochemical derangement
in these children separates this syndrome both from the classical picture
of an acquired Cbl deficiency syndrome and from the "typical"
presentation of intracellular defects of Cbl metabolism.
To understand where the syndrome of TC II deficiency fits into the
spectrum of Cbl-related metabolic disease, one must analyze the
significance of the pleomorphic nature of the manifestations of Cblrelated disorders.'

Although most patients with acquired Cbl deficiency

have methylmalonic acidemia, some do not (43).

One might explain

this phenomenon by suggesting that in these patients, Cbl deficiency
causes megaloblastic anemia and neurologic disorders in susceptible

tissues before it is severe enough to cause measurable changes in
blood or urine levels of methylmalonic acid or homocysteine.

This argu¬

ment would explain why acquired Cbl deficiency does not present with the
metabolic emergencies typical of intracellular defects leading to abso¬
lute deficiencies of Cbl-dependent enzyme function.

In this context,

the implication of the syndrome associated with TC II deficiency is
that here too, the intracel1ular Cbl deficiency is not absolute in all
tissues, i.e., that some Cbl is capable of entering cells by a non-TC IImediated mechanism.

This suggestion is supported by the observation of

the impressive response of these patients to high doses of Cbl and
leads to the hypothesis that human cells possess a mechanism for the up¬
take and metabolism of free cobalamin.
investigate that hypothesis.
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This study was undertaken to

MATERIALS AND METHODS
Materials
Eagle's Minimal Essential Medium and Earle's Balanced Salt Solu¬
tion were obtained from Grand Island Biological Co., Grand Island, NY.
Fetal calf serum was purchased from Flow Laboratories, Inc., Rockville, MD.
HEPES was obtained from Calbiochem, San Diego, CA.

Chloroquine was pur¬

chased from Sigma Chemical Co.; N-Ethylmaleimide (NEM) was purchased
from Eastman.

Anti-human TC II antiserum was kindly provided by Dr. R.H.

Allen, Division of Hematology, University of Colorado Medical Center.
Cyano[

57

Co]cobalamin (CN-[

57

Co]Cbl) was purchased from Amersham/Searle.

Cell Culture
Initial experiments were carried out with a representative control
line of human diploid skin fibroblasts (line 87).

This line has been

used in previous work (40,41) to investigate the TC II-mediated uptake
of Cbl.

Comparative experiments were then performed using a diploid

skin fibroblast line (line 181) from a patient with TC II deficiency (77).
Cells were grown in Eagle's minimal essential medium suDplemented with 1
percent nonessential amino acids, 10 percent fetal calf serum, and 100
yg/ml kanamycin.

There is no detectable TC II in fetal calf serum (41).

Fetal calf serum contains approximately 300-500 pg/ml Cbl, bound to Rbinder.

Stock cultures were grown in 32 oz glass bottles which were

gassed with 5 percent CO^/PB percent air, tightly capped, and placed in a
37° incubator.

For uptake studies, cells were seeded on 100 x 15 mm Falcon

plastic tissue culture plates at 7.5-8.5 x 10

cell/dish and placed in a

37° incubator with 5 percent 00^/95 percent air atmosphere.

For Sephadex

G150 column experiments, cells were grown at 37° in 150 cm

plastic flasks

which were gassed and tightly capped.
2 x 106 cells/bottle.

Bottles were seeded at approximately

Cells became confluent on the third day after

plating; experiments were performed on day 4.
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Uptake of Free CN-f^ColCbl
Uptake experiments were carried out in serum-free medium.

Pre¬

liminary results established that uptake was comparable in the presence
or absence of supplementary amino acids.

Therefore, subsequent experi¬

ments were done in Earle's balanced salt solution (EBSS).
ception of concentration studies, medium contained CN-[

57

With the exCo]Cbl at a con¬

centration of 30 pg/ml, a molar concentration equivalent to the Cbl con¬
centration of medium with 10 percent serum saturated with Cbl.

The growth

medium was aspirated and the cell monolayers washed twice with 5 ml
Dulbecco's Ca++- and Mg++-free phosphate-buffered saline (PBS).
of incubation medium or EBSS was added.

Six ml

Initial experiments were carried

out at 37° in medium with 10 mM HEPES on a revolving shaker to prevent
contribution of an unstirred fluid monolayer.

It was determined that

shaking had no effect on uptake, and subsequent experiments were carried
out without shaking in a humidified C0^ incubator.

After incubations

of 30 min to 8 hr, the cells v/ere washed four times with 5 ml PBS, dis¬
solved in 1 ml of 0.2 N NaOH, and transferred to a plastic counting
tube.

The dish was then rinsed twice using 1 ml of 0.2 N NaOH and

rinses combined with the solubilized cells.

The solubilized cells were

counted in a Packard automatic gamma scintillation counter.

An aliquot

was assayed for cell protein by the Lowry method (80), and uptake
expressed as pg Cbl/mg cell protein.
Studies with metabolic inhibitors were performed by preincubation
with inhibitor for a defined interval prior to assay of uptake of
CN-[

57

Co]Cbl.

Uptake was then studied in incubation medium containing

the same concentration of inhibitor.

Concentrations of NaF, cyclo-

heximide, and chloroquine were chosen to match those concentrations
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which were used to evaluate the inhibitor profile of TC II-mediated
uptake in this system (41).

KCN was used in concentrations known to

inhibit respiration (81), and NEM concentration was empirically adjusted
to find a level that did not prove lethal to fibroblasts.

In these

experiments, total uptake (binding and internalization) was distinguished
from internalization by harvesting with trypsin-EDTA.

After incubation

of cells at 4°, trypsin-EDTA removed 95-98% of cel 1-associated
radioactivity (data not shown).
applies to

57

57

Co

Hence, the term "internalization" here

Co activity associated with cells which is not releasable

by trypsin, and "uptake" applies to total cel 1-associated
associated with cells after harvesting with 0.2 N NaOH.

57

Co activity

For experi¬

ments with metabolic inhibitors, cells were harvested by addition of 1
ml of trypsin-EDTA.
were floating.

The dishes were incubated at 37° until the cells

The cell suspension was then transferred to a 15 ml conical

centrifuge tube and the dish washed with ice-cold growth medium. The
suspension was centrifuged at 1800 g for 3 min at 4°C.
was removed to a plastic counting tube and counted.

The supernatant

The cell pellet

was dissolved in 0.2 N NaOH, counted, and cell protein determined.
Intracellular Metabolism of Free Cbl
To determine the fate of CN-[

57

Co]Cbl taken up by monolayers, cell

extracts were prepared and analyzed by Sephadex G150 profiles.

The cells

were harvested with trypsin and the cell pellet was sonicated for 3x15
sec intervals.

The extract was centrifuged at 18,000 g for 10 min, then

the supernatant was loaded onto a Sephadex G150 (Pharmacia) column and
eluted with buffer containing 0.15 M NaCl and 50 mM potassium phosphate,
pH 7.4.

1 .85 ml fractions were collected and counted for

57

Co radioactivity.

For column profiles in the presence of chloroquine, the 6 hr uptake
was preceded by a one hr preincubation with chloroquine.
-
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RESULTS
Kinetics of Free CN-[^Co]Cbl Uptake
For a preliminary estimate of the magnitude of free CN-[
uptake, an experiment was performed comparing uptake of CN-[

57

57

Co]Cbl

Co]Cbl

at 30 pg/ml in serum-free medium to that in medium containing 10 percent
human serum.

After a two hour incubation, cells in serum-free medium took

up 1.43 pg/mg protein, as compared with an uptake of 6.41 pg/mg protein
by monolayers in 10 percent human serum.

The latter value is comparable

to results of previous experiments with fibroblasts (82).
Fig. 4 shows the time course of uptake in serum-free medium from
ten min to eight hrs.

Uptake is a biphasic process:

the first component

is rapid, nonlinear, and complete within less than 30 min; the second
phase is linear and does not plateau within eight hrs.

Saturabilit.y of Uptake
The uptake of free CN-[
shown in Fig. 5a.

57

Co]Cbl as a function of concentration is

To identify non-specific uptake, parallel plates

were incubated at each concentration up to 90 pg/ml in the presence
of a large excess of unlabelled CN-Cbl.

By comparing uptake in the

presence and absence of an excess of unlabelled Cbl, the concentra¬
tion curve can be resolved into two components (Fig. 5b).

Uptake in

the presence of unlabelled CN-Cbl is linearly proportional to concen¬
tration and nonsaturable; this uptake is defined as non-specific.
Subtraction of non-specific uptake from total uptake allows derivation
of a curve representing an uptake process which is nonlinear and
saturable.
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nt*^CVVS
UPTAKE

FIGURE 4.

Time course of uptake of free Cbl. Cells were incubated at
37° in serum-free medium with 30 pg/ml CN-[57Co]Cbl and
solubilized in 0.2 N NaOH. This curve and others to follow
show results of a representative experiment; each point is
the average of duplicate determinations.
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FIGURE 5.

Uptake of CN-[ Co]Cbl as a function of concentration. Cells
incubated at 37° for two hours. Fig. 5b reproduces part of
curve 5a indicated in box. At these concentrations, parallel
plates were incubated in the presence of an excess of unlabelled
CN-Cbl. Dotted line shows derived saturable component of uptake.
See text for details. Closed circles = total uptake. Open
circles = nonspecific uptake in the presence of excess unlabelled
CN-Cbl.
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Uptake of OH-Cbl
To determine whether OH-Cbl was equally active in this system,
an experiment was performed comparing the effectiveness of unlabelled
OH-Cbl and unlabelled CN-Cbl in preventing the uptake of CN-[57Co]Cbl.
Fig. 6 reveals that CN-Cbl and OH-Cbl are equally effective in competing for uptake.

Subsequent studies of the uptake of 0H-[

57

Co]Cbl

as a function of concentration showed uptake comparable to the uptake
of CN-[57Co]Cbl (Fig. 7).

Effect of Metabolic Inhibitors on CN-T^ColCbl Internalization
Experiments were performed with metabolic inhibitors to determine
the metabolic requirements of the internalization of Cbl.
summarized in Table 1.

Results are

Cycloheximide (50 pM), a protein synthesis

inhibitor which has been shown previously to inhibit internalization
of the TC 11-Cbl complex (41), inhibits CN-[^7Co]Cbl internalization
by 80 percent.

NaF (100 pM), a inhibitor of glycolysis, which inhibits

TC 11-Cbl internalization by 50 percent (41), has no effect on the in¬
ternalization of free Cbl.

KCN in concentrations sufficient to inhibit

respiration (10 mM) inhibits free Cbl internalization by only 10 percen
N-ethylmaleimide, which binds sulfhydryl groups, is lethal to cells at
100 pM; at 10 pM, it inhibits internalization of CN-[^7Co]Cbl by 76
percent.

Chloroquine (5n pM), an inhibitor of lysosomal hydrolase

activity, inhibits internalization 25 percent after a 1 hr preincuba¬
tion and 4G percent after a 2 hr preincubation.
the effects of chloroquine are presented below.
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Further studies of

FIGURE 6.

Competition for CN-[" Co]Cbl uptake by excess of unlabelled
CN-Cbl and OH-Cbl. Cells incubated at 37° for two hours
with 30 pg/'ml CN-[5?Co]Cbl. Results expressed as percent of
control uptake in the absence of unlabelled Cbl.

-

28

-

29

FIQURE G>

FIGURE 7.

Concentration curve for QH-Cbl.
two hours.
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Cells incubated at 37° for

TABLE I
Inhibitor

% Inhibition of Internalization
Normal Cells

TC II-deficient Cells

80%

44%

NaF (100 pM)

0%

0%

KCN (10 mM)

10%

31%

NEM (10 mM)

76%

41%

25-40%

0-10%

Cycloheximide (50 pM)

Chloroquine (50 yM)

Table 1:

Inhibitor profile for normal and TC II-deficient cells. Cells
preincubated in inhibitor for 1 or 2 hrs prior to uptake. In¬
cubation medium for uptake contained 30 pg/ml CN-[57Co]Cbl and
inhibitor. After 2 hr uptake, cells were harvested with trypsin
EDTA and inhibition expressed as % inhibition of internalization
Each value is an average of duplicate determinations. A repre¬
sentative experiment is shown.
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Intracel 1 ular Metabolism of CN-f^ColCbl
To confirm that free Cbl taken into cells is metabolized to active
coenzymes, a cell extract of monolayers incubated in 30 pg/ml CN-[
for six hours was loaded on a Sephadex G150 column.
is shown in Fig. 8.

There are three peaks of

57

57

Co]Cbl

The elution profile

Co activity:

the first

corresponds to the Cbl-dependent apoenzyme (85), the third represents
free Cbl.

The second peak co-chromatographs with TC II.

To confirm

that this peak is, in fact, TC II, a second cell extract was prepared
after a six hour incubation.

Prior to loading onto Sephadex G150 columns,

half was incubated for one hour at 4° with control rabbit serum and the
other half with purified rabbit anti-TC II antiserum.

The two sera were

preincubated with unlabelled CN-Cbl before addition to the sonicate, to
saturate endogenous TC II which was found to exist in rabbit serum (data
not shown).
Fig. 9.

The results of the two Sephadex G150 profiles are shown in

The three peaks noted above are seen again in the profile of

the sonicate incubated with control serum; in the sonicate exposed to
anti-TC II antiserum, the second peak moves to the void volume, confirm¬
ing that this peak is, in fact, TC II.
make TC II.

Hence, it appears that fibroblasts

To determine whether the cells also secrete TC II into the

medium, an elution profile of post-incubation medium was obtained.
expected, over 90 percent of

57

As

Co activity was associated with free Cbl;

however, there was a measurable peak of TC II-associated radioactivity
representing four percent of total

57

Co activity.

Studies with TC II-Deficient Fibroblasts
The unexpected discovery that normal fibroblasts make TC II
suggested that the saturable component of uptake might, in fact,
be TC II-mediated.

To investigate this possibility, experiments

32
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C?M
^Co

FIGURE 8.

Sephadex G150 elution profile of normal fibroblast extract
after six hour uptake of CN-[57c0]Cbl.
See text for details.
Arrow indicates void volume. Recovery was 100 percent.
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FIGURE 9.

Sephadex G150 elution profile for six hour uptake of
CN-[57co]Cbl by normal fibroblasts.
Upper figure shows
profile of cell extract incubated for one hour at 4° with
control rabbit serum; lower figure shows profile of ex¬
tract incubated at 4° with anti-TC II antiserum.
For
details, see text.
Recovery was 100 percent.
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were repeated with fibroblasts derived from TC II-deficient patients.
The uptake of free Cbl by control and TC II-deficient fibroblasts as a
function of time and concentration is shown in Fig. 10 and 11.

Though

at 30 pg/ml the uptake over time is greater for the control cells than
the TC II-deficient cells, this difference is not seen at higher concen¬
trations.

Once again, the curves for the TC II-deficient cells are bi-

phasic, suggestive of a nonlinear, saturable component of uptake.
A Sephadex G150 elution profile was obtained for the TC II defi¬
cient cells.

Because the uptake at six hours at 30 pg/ml was so much

lower for this cell line, difficulty was encountered in obtaining uptake
of sufficient counts to run a column.

Consequently, the profile was

done after a six hour incubation in 90 pg/ml CN-[
was also obtained at 90 pg/ml in control cells.
are compared in Fig. 12.
cell are remarkable.

Co]Cbl,

A profile

The two elution patterns

Two characteristics of the TC II deficient

First, the profile of the mutant cells has no

peak corresponding to TC II, thus confirming that these cells are
truly deficient in the transport protein.

Second, the cells also con¬

tain a reduced proportion of free Cbl-associated radioactivity.
Almost all of the radioactivity is associated with the single peak
corresponding to the Cbl-dependent apoenzymes.

Inhibitor Profile
The inhibitor profile for TC II-deficient cells is compared to that
of normal cells in Table 1.

Cycloheximide and NEM inhibit CN-[

57

internalization significantly, though less than in normal cells.

Co]Cbl
As in

controls, NaF does not inhibit internalization of the free vitamin.

KCN

inhibits internalization of Cbl by 31%, considerably more than in control
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FIGURE 10.

Comparison of CN-[57Co]Cbl uptake by control and TC IIdeficient fibroblasts as a function of time.
Closed
circles = Control, line 87. Open circles = TC II-deficient
cells, line 181.

-

37

-

38

-

FIGURE 10

FIGURE 11.

Comparison of CN-[^Co]Cbl uptake by control and TC IIdeficient fibroblasts as a function of concentration.
Closed circles = control, line 87. Open circles = TC II
deficient cells, line 181.
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FI&UR.E 11

FIGURE 12.

Comparison of Sephadex G150 profile of cell extracts of
control (87) and TC II-deficient (181) fibroblasts after 6 hr
incubation in 90 pg/ml CN-[57Co]Cbl.
Free Cbl-associated
57Co activity represents 25 percent of non-TC II associated
activity in control cells, as compared with 10 percent of
57Co activity in mutant cells. Arrow indicates void volume.
Recovery was 100 percent.
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cells.

This was noted to be associated with a 15 percent decrease in

cell protein in those dishes, and may indicate that for some reason,
KCN is especially toxic to these cells.

Effect of Chloroquine on Uptake of Free Cbl
To investigate the role of lysosomes in the uptake process and
to further analyze the inhibition of free Cbl uptake by chloroquine a
Sephadex G150 profile was obtained of a cell extract of fibroblasts
(line 87) which had been preincubated for one hour in chloroquine and
then incubated for six hours in uptake medium with 90 pg/ml CN-[
and 50 pM chloroquine.

The profile is shown in Fig. 13.

57

Co]Cbl

Uptake in

the presence of chloroquine leads to peaks of free Cbl and apoenzymeassociated

57

Co activity which are much reduced over control conditions

(compare to Fig. 12).

The TC II-associated activity is greatly increased.

Internalization of Cbl by TC II-deficient cells in the presence
of chloroquine (Fig 14) is essentially unchanged.

There is still a

single major peak of radioactivity associated with apoenzymes and
little free CN-[^7Co]Cbl.
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FIGURES 13 and 14.

Sephadex G150 uptake profile of cell extract of
control cells (line 87) and TC II-deficient cells
(line 181) in presence of chloroquine. Cells were
preincubated for one hour in 50 pM chloroquine,
followed by a 6hr incubation in 90 pg/mi CM-[”Co]Cbl
and 50 pM chloroquine. See text for details.
Free Cbl peak represents 13 percent of 57g0 activity
in mutant cells, and 10 percent of ^Co activity in
control cells. TC II-associated activity in control
cells is increased from 27 percent under control
conditions (Fig. 12) to 45 percent of 57g0 activity;
apoenzyme-associated activity is decreased from 36
percent to 22 percent.
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DISCUSSION
The experiments described above lead to two major conclusions:
1) that normal human diploid fibroblasts in tissue culture synthesize
TC II and secrete it into culture medium, a property not observed in
cultured mutant fibroblasts derived from patients with serum deficiency
of that protein, and 2) that normal and TC II-deficient cells share a
mechanism for the uptake of free Cbl which is independent of TC II.
Evidence for the synthesis and secretion of TC II by fibroblasts
in culture lies in the observation of a CN-[

CojCbl binding capacity

which co-chromatographs with TC II on Sephadex G150, which reacts with
purified anti-human TC II antiserum, and which accumulates in incubation
medium over time.

The observation that TC II-synthetic capability is

expressed by fibroblasts in culture allows the further characterization
of the defect which is expressed as complete absence of TC II in serum.
Fibroblasts cultured from TC II-deficient patients lack Cbl-binding
capacity in the TC II region of the Sephadex G150 profile; this sug¬
gests that these cells either do not synthesize TC II or that they
synthesize an abnormal protein which is unable to bind Cbl.
Although the synthesis of TC II by human cells in culture has not
been described previously, synthesis of the transport protein has been
reported in cultured rat parenchymal cells (84) and mouse fibroblasts
(85).

The j_n vivo significance of the i_n vitro synthesis of a serum

transport protein by cell lines serially propagated in culture is
difficult to evaluate.

The production of TC II has also been observed

in isolated, perfused dog heart, spleen, kidney, and liver (86).

The

latter two organs have been considered sites of synthesis and secretion
of TC II (28), but the heart and spleen would be unusual secretory sources
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of plasma transport proteins; their production of TC II argues for wide¬
spread endogenous synthesis of TC II in mammalian tissues.
If these observations in vitro are considered to reflect wide¬
spread synthesis of TC II in vivo, one might then speculate as to the
functional significance of that synthesis.

Hall and Rappazzo (28) have

reported that the capacity for uptake of free Cbl is enhanced in those
organs which produce TC II.

However,

one cannot

suggest that

endogenous TC II functions to facilitate uptake of free Cbl, since, with
the possible exception of the liver, peripheral tissues are exposed only
to Cbl which is already bound to transport proteins.

Alternatively,

peripheral production of TC II may be an evolutionary vestige with no
physiologic significance, although the possibility that TC II plays an
as-yet-unknown intracellular function has not been excluded.
These experiments have also identified a

TC II-independent uptake

process for Cbl'common to both control and TC II-deficient cells.
cess is biphasic, with a saturable,

This pro¬

specific component which is

saturated at physiologic concentration and which reaches asteady state within
thirty minutes.

Uptake is inhibited by inhibitors of protein synthe¬

sis and by disulfide bond reductants; it is relatively unaffected by
inhibitors of glycolysis and respiration.

These characteristics sug¬

gest a specific, receptor-mediated process which is energy-independent;
it is most consistent with a process of facilitated diffusion.
A free Cbl-specific receptor has been described in bacterial
systems (87,88); Fiedler-Nagy et al. have also reported specific bind¬
ing of free Cbl to preparations of rat liver membranes (89).

The

latter is the only other evidence to date of a specific uptake mechanism
for free Cbl in higher animals.

The results reported in rat liver
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membranes are remarkable for the observation of binding of free Cbl of
a magnitude similar to that mediated by TC II.

The Fiedler-Nagy experi¬

ments measured binding, rather than total uptake.

However, if the first

component of uptake is considered to represent binding, as was proposed
in early studies of TC II-Cbl uptake (36,37), the observation by FiedlerNagy of approximately equal binding of free Cbl and TC 11-Cbl differs
from previous observations of facilitation of Cbl uptake (binding and
internalization) by TC II (34,35), as well as from the results obtained
in the present study.

The reason for this discrepancy is unclear,

although the possibility exists that this unusual avidity for free
Cbl is a property unique to liver parenchyma.

Such an avidity might

explain the clinical manifestations of TC II deficiency and provide
insight into the physiologic significance of the saturable uptake
process for free Cbl.

The uptake of free Cbl when present in physiologic

concentrations is inadequate in stem cells of rapidly proliferating
tissue to prevent megaloblastic transformation, mucosal ulcerations,
and intestinal malabsorption.

However, one may infer that it is adequate

in liver parenchyma to prevent methylmalonic acidemia and homocystinuria,
since these abnormalities do not develop.

Whether this suggests that

the liver's demand for Cbl is less, or its avidity for the vitamin
more than that of stem cells, is unclear.
At the pharmacologic doses which successfully treat TC II deficiency,
which leads to serum Cbl concentrations of 2000-5000 pg/ml, uptake is
primarily nonspecific.

Whether uptake of free Cbl at these concentrations

occurs by simple diffusion, bulk phase pinocytosis, or some other non¬
specific process remains unclear.
Comparison of the Sephadex G150 profiles of normal and TC II
deficient cells exposed to CN-[

-

57

Co]Cbl provides further insight into
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the mechanism of uptake of free Cbl.

The absence of significant free

Cbl-associated radioactivity in TC II-deficient cells suggests that the
presence of intracel lular free Cbl is a characteriStic only of TC IImediated uptake.

These observations could be explained by the role of

lysosomes in the metabolism of the TC 11-Cbl complex as follows:

as

discussed in the introduction, the TC II-Cbl complex is thought to be
taken up intact by adsorptive endocytosis and digested within lysosomes
this results in the release of free Cbl and its subsequent transport
out of the lysosome into the cytoplasm where it can be metabolized to
its active forms.
57

Thus, it seems possible that the free Cbl-associated

Co activity in normal fibroblasts may represent Cbl still residing

within lysosomes where it is unavailable for immediate conversion to
coenzymes.

It then follows that the association of all

57

Co activity

in mutant cells with Cbl-dependent enzymes implies that the internali¬
zation of Cbl by these cells is followed by synthesis of coenzymes and
association with apoenzymes with sufficient rapidity to prevent
accumulation of free Cbl; i.e., that free Cbl is not taken up into
lysosomes, but enters the cytoplasm directly.

This hypothesis is

supported by the observation that chloroquine, which leads to the
accumulation of TC 11-Cbl within lysosomes (41), abolishes most of the
free Cbl-associated radioactivity in normal cells.

Thus it appears

that the uptake of free Cbl by fibroblasts cccurs by receptor-mediated
facilitated diffusion which leads to direct entry of the vitamin to
the cytoplasm.
If this uptake process is considered to occur in vivo, one might
again speculate as to the physiologic significance of the observations
which have been made.

Since the TC II-mediated uptake process is more
-
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efficient and is certainly the crucial means of uptake in those cells
which have large Cbl requirements, it is not obvious what evolutionary
pressures might exist for maintenance of a mechanism for the uptake of
free Cbl.

There is nothing to exclude the possibility that the mechanism

observed in these experiments is merely a remnant of an evolutionary
period preceding the development of more efficient uptake processes.
However, there is a place for transport systems for free Cbl in mammalian
tissues.

Though the plasma transport and cellular uptake of Cbl is

mediated by TC II, intracellular metabolism of the TC II-Cbl complex
requires the movement of Cbl out of lysosomes and into mitochondria.
This suggests a scheme whereby the free Cbl uptake system described
here might have a role in normal Cbl metabolism.

In the course of endo-

cytosis of the TC 11-Cbl complex, a portion of the plasma membrane
becomes first incorporated into a phagosome, and subsequently becomes
part of the lysosomal membrane.
becomes everted.

In this process the plasma membrane

If that membrane fragment contained a receptor for

free Cbl capable of mediating facilitated diffusion of Cbl into the
cell, it might then neatly fulfill a function as a mediator of free
Cbl passage out of the lysosome (Fig. 15).

Certainly this proposed

mechanism at present 1 -jes in the realm of pure speculation; it does,
however, describe a cellular economy which is more appealing than the
relegation of the uptake process to the category of evolutionary
castoffs which have lost their function.
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FIGURE 15.

Proposed mechanism of role of free-Cbl uptake process
in intracellular Cbl metabolism. See text for details.
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